The tweet was deleted by the author.
But we saved everything 🙂.
Sandra Hammer, PhD, of Atossa Therapeutics, Inc. is set to deliver an oral presentation at the MDA Clinical and Scientific Conference.
Her research outlines how (Z)-Endoxifen restores muscle performance and reduces damage biomarkers in Mdx5cv dystrophic mice, marking a promising preclinical advance for Duchenne muscular dystrophy therapies. The presentation is scheduled for March 11th at 9:00 AM EST. The event will gather scientific and clinical experts to discuss recent progress in muscular dystrophy research.
Hammer’s latest findings on (Z)-Endoxifen’s therapeutic potential in Duchenne muscular dystrophy build upon Atossa Therapeutics’ broader efforts to advance precision endocrine therapies. This work underscores the company’s ongoing commitment, as detailed in their recent progress on the Z-endoxifen platform targeting both oncology and DMD with molecular precision. Further context on the framework for risk reduction in breast cancer using Z-Endoxifen can be found in the company’s comprehensive strategy for prevention.